PL2018169T3 - Zastosowanie 4,17β-dihydroksyandrost-4-en-3-onu do leczenia raków - Google Patents

Zastosowanie 4,17β-dihydroksyandrost-4-en-3-onu do leczenia raków

Info

Publication number: PL2018169T3
Authority: PL; Poland
Prior art keywords: dihydroxyandrost; ene; beta; treating cancers; hormone
Prior art date: 2006-05-12

Application number

PL07725140T

Other languages

English (en)

Inventor

Alexander Tobias Teichmann

Original Assignee

Mabel Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-12

Filing date

2007-05-11

Publication date

2011-04-29

2007-05-11 Application filed by Mabel Gmbh filed Critical Mabel Gmbh

2011-04-29 Publication of PL2018169T3 publication Critical patent/PL2018169T3/pl

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
BQOIJSIMMIDHMO-FBPKJDBXSA-N 4-Hydroxytestosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1O BQOIJSIMMIDHMO-FBPKJDBXSA-N 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
229940088597 hormone Drugs 0.000 abstract 1
239000005556 hormone Substances 0.000 abstract 1
108091008039 hormone receptors Proteins 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PL07725140T 2006-05-12 2007-05-11 Zastosowanie 4,17β-dihydroksyandrost-4-en-3-onu do leczenia raków PL2018169T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US74712406P	2006-05-12	2006-05-12
EP06009894A EP1854465A1 (en)	2006-05-12	2006-05-12	Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
EP07725140A EP2018169B1 (en)	2006-05-12	2007-05-11	Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
PCT/EP2007/004220 WO2007131736A2 (en)	2006-05-12	2007-05-11	Use of 4, 17 beta-dihydroxyandrost-4-ene-3-one for treating cancers

Publications (1)

Publication Number	Publication Date
PL2018169T3 true PL2018169T3 (pl)	2011-04-29

Family

ID=37075285

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL07725141T PL2018170T3 (pl)	2006-05-12	2007-05-11	Lek na raka sutka
PL07725140T PL2018169T3 (pl)	2006-05-12	2007-05-11	Zastosowanie 4,17β-dihydroksyandrost-4-en-3-onu do leczenia raków

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL07725141T PL2018170T3 (pl)	2006-05-12	2007-05-11	Lek na raka sutka

Country Status (15)

Country	Link
US (3)	US9138477B2 (pl)
EP (3)	EP1854465A1 (pl)
JP (2)	JP5363310B2 (pl)
KR (2)	KR101403893B1 (pl)
CN (2)	CN101443016B (pl)
AT (1)	ATE487483T1 (pl)
AU (2)	AU2007251823B2 (pl)
CA (2)	CA2652057C (pl)
DE (1)	DE602007010447D1 (pl)
DK (2)	DK2018170T3 (pl)
ES (2)	ES2391839T3 (pl)
PL (2)	PL2018170T3 (pl)
PT (2)	PT2018169E (pl)
SI (2)	SI2018170T1 (pl)
WO (2)	WO2007131736A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1854465A1 (en)	2006-05-12	2007-11-14	Alexander Tobias Teichmann	Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
EP2060261B1 (en)	2007-11-13	2016-03-09	Athenion AG	C-19 steroids for cosmetic uses
ES2628507T3 (es) *	2007-11-13	2017-08-03	Athenion Ag	Esteroides C-19 para el tratamiento de la celulitis
FR2964323B1 (fr) *	2010-09-08	2012-11-09	Jean Pierre Raynaud	Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
WO2012044830A1 (en) *	2010-10-01	2012-04-05	Indiana University Research And Technology Corporation	Treatment of symptoms associated with menopause
ES2694582T3 (es)	2011-01-31	2018-12-21	Lucolas-M.D. Ltd.	Combinaciones de inhibidores de aromatasa y antioxidantes
WO2015055179A1 (de) *	2013-10-15	2015-04-23	Chelac Holding Gmbh	Steroid-carbonsäureester, zusammensetzungen, enthaltend steroid-carbonsäureester und verwendung dieser bei lokal topischer applikation für kosmetische oder dermatologische zwecke
PT3040075T (pt) *	2014-12-30	2017-12-20	Curadis Gmbh	Esteróides c-19 para inibição da neovascularização
US20190201526A1 (en) *	2016-09-07	2019-07-04	The Wistar Institute Of Anatomy And Biology	Methods and Compositions for Treating Cancers by Inhibiting Estrogen Signaling in Myeloid-Derived Suppressor Cells
CN108727453A (zh) *	2017-04-20	2018-11-02	华东理工大学	新型pd-1抑制剂及其应用
EP3632445A1 (en) *	2018-10-04	2020-04-08	Curadis GmbH	Combinations with a c-19 steroid for treating cancers
RU2679625C1 (ru) *	2018-11-08	2019-02-12	Ильясов Шамиль Сионович	ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-6-ОКСА-7β-МЕТИЛ-D-ГОМО-8α-ЭСТРА-1,3,5(10)-ТРИЕН-17а-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ВКЛЮЧАЯ ТРИЖДЫ-НЕГАТИВНУЮ ФОРМУ, И СПОСОБ ЕГО ПОЛУЧЕНИЯ
EP3666276A1 (en) *	2018-12-14	2020-06-17	dcic Biopharmaceutical Limited	Medication against estrogen-receptor beta (erbeta) positive breast tumor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA639855A (en)		1962-04-17	Societa Farmaceutici Italia	4-halo-3-keto-.delta.4-steroids
BE552152A (pl) *
US2744120A (en)	1953-01-14	1956-05-01	Olin Mathieson	1-dehydrotestololactone
US2762818A (en) *	1955-05-26	1956-09-11	Searle & Co	4-hydroxytestosterone and esters thereof
US4235893A (en)	1978-05-08	1980-11-25	Brodie Angela M	Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
US4322416A (en)	1980-06-27	1982-03-30	Merrell Dow Pharmaceuticals Inc.	10-Alkynyl steroids
US4289762A (en) *	1980-06-27	1981-09-15	Merrell Dow Pharmaceuticals Inc.	10-(1,2-Propadienyl) steroids as irreversible aromatase inhibitors
DE3121153A1 (de)	1981-05-22	1982-12-09	Schering Ag, 1000 Berlin Und 4619 Bergkamen	"verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
DE3362176D1 (en)	1982-07-14	1986-03-27	Akzo Nv	Novel 19-thio-androstane derivatives
GB8721384D0 (en)	1987-09-11	1987-10-21	Erba Farmitalia	17-substituted andro-sta-1 4-dien-3-one derivatives
CA2386095A1 (en)	1999-09-30	2001-04-05	Hollis-Eden Pharmaceuticals, Inc.	Therapeutic treatment of androgen receptor driven conditions
DE10049736A1 (de) *	2000-09-29	2002-04-18	Jenapharm Gmbh	17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE10054294A1 (de)	2000-11-02	2002-05-16	Heinrich Wieland	Topische Behandlung bei der Mastalgie
US20030229063A1 (en) *	2002-06-05	2003-12-11	Llewellyn William Charles	Use of 4-hydroxytestosterone to lower estrogen levels in humans
US20030049307A1 (en) *	2002-08-15	2003-03-13	Gyurik Robert J.	Pharmaceutical composition
GB2398495B (en) *	2003-01-23	2007-08-22	Kent G Lau	A drug delivery preparation comprising at least one anti-tumour drug and a topical carrier for the drug
ATE417041T1 (de) *	2003-08-07	2008-12-15	Schering Corp	Neue farnesylproteintransferaseinhibitoren als antitumormittel
US7935724B2 (en) *	2003-10-09	2011-05-03	Merck Hdac Research, Llc	Thiophene and benzothiophene hydroxamic acid derivatives
CA2549518A1 (en) *	2003-12-12	2005-07-14	University Of Rochester	Non-androgen dependent roles for androgen receptor and non-androgen related inhibitors of androgen receptor
NZ552091A (en) *	2004-07-16	2009-09-25	Pfizer Prod Inc	Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
EP1854465A1 (en) *	2006-05-12	2007-11-14	Alexander Tobias Teichmann	Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers

2006
- 2006-05-12 EP EP06009894A patent/EP1854465A1/en not_active Withdrawn
2007
- 2007-05-11 WO PCT/EP2007/004220 patent/WO2007131736A2/en active Application Filing
- 2007-05-11 KR KR1020087027498A patent/KR101403893B1/ko not_active Expired - Fee Related
- 2007-05-11 PT PT07725140T patent/PT2018169E/pt unknown
- 2007-05-11 CA CA2652057A patent/CA2652057C/en not_active Expired - Fee Related
- 2007-05-11 AU AU2007251823A patent/AU2007251823B2/en not_active Ceased
- 2007-05-11 US US12/300,508 patent/US9138477B2/en not_active Expired - Fee Related
- 2007-05-11 KR KR1020087027501A patent/KR101403895B1/ko not_active Expired - Fee Related
- 2007-05-11 DK DK07725141.1T patent/DK2018170T3/da active
- 2007-05-11 JP JP2009508260A patent/JP5363310B2/ja not_active Expired - Fee Related
- 2007-05-11 US US12/300,503 patent/US9114163B2/en not_active Expired - Fee Related
- 2007-05-11 EP EP07725140A patent/EP2018169B1/en not_active Not-in-force
- 2007-05-11 PL PL07725141T patent/PL2018170T3/pl unknown
- 2007-05-11 DE DE602007010447T patent/DE602007010447D1/de active Active
- 2007-05-11 SI SI200731039T patent/SI2018170T1/sl unknown
- 2007-05-11 AT AT07725140T patent/ATE487483T1/de active
- 2007-05-11 PL PL07725140T patent/PL2018169T3/pl unknown
- 2007-05-11 CN CN2007800172059A patent/CN101443016B/zh not_active Expired - Fee Related
- 2007-05-11 WO PCT/EP2007/004221 patent/WO2007131737A2/en active Application Filing
- 2007-05-11 SI SI200730452T patent/SI2018169T1/sl unknown
- 2007-05-11 CA CA2651354A patent/CA2651354C/en not_active Expired - Fee Related
- 2007-05-11 PT PT07725141T patent/PT2018170E/pt unknown
- 2007-05-11 CN CN2007800172379A patent/CN101443017B/zh not_active Expired - Fee Related
- 2007-05-11 DK DK07725140.3T patent/DK2018169T3/da active
- 2007-05-11 ES ES07725141T patent/ES2391839T3/es active Active
- 2007-05-11 EP EP07725141A patent/EP2018170B1/en active Active
- 2007-05-11 AU AU2007251822A patent/AU2007251822B2/en not_active Ceased
- 2007-05-11 ES ES07725140T patent/ES2355530T3/es active Active
- 2007-05-11 JP JP2009508259A patent/JP5363309B2/ja not_active Expired - Fee Related
2015
- 2015-07-30 US US14/813,715 patent/US9610292B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DK2018169T3 (da)	2011-02-07
ES2355530T3 (es)	2011-03-28
EP2018170B1 (en)	2012-07-25
EP2018169A2 (en)	2009-01-28
PL2018170T3 (pl)	2013-01-31
WO2007131736A2 (en)	2007-11-22
US20090111784A1 (en)	2009-04-30
JP2009536931A (ja)	2009-10-22
KR101403893B1 (ko)	2014-06-20
AU2007251822B2 (en)	2012-08-16
CN101443016B (zh)	2012-09-05
JP2009536932A (ja)	2009-10-22
CA2651354C (en)	2015-11-17
WO2007131736A3 (en)	2008-03-06
DK2018170T3 (da)	2012-10-22
KR20090009855A (ko)	2009-01-23
KR20090010189A (ko)	2009-01-29
SI2018170T1 (sl)	2012-12-31
CN101443017A (zh)	2009-05-27
ES2391839T3 (es)	2012-11-30
CN101443017B (zh)	2013-07-31
EP2018170A2 (en)	2009-01-28
AU2007251823A1 (en)	2007-11-22
US9138477B2 (en)	2015-09-22
AU2007251822A1 (en)	2007-11-22
PT2018169E (pt)	2011-01-19
SI2018169T1 (sl)	2011-02-28
JP5363310B2 (ja)	2013-12-11
EP2018169B1 (en)	2010-11-10
DE602007010447D1 (de)	2010-12-23
WO2007131737A2 (en)	2007-11-22
US9610292B2 (en)	2017-04-04
US9114163B2 (en)	2015-08-25
US20160030448A1 (en)	2016-02-04
JP5363309B2 (ja)	2013-12-11
PT2018170E (pt)	2012-10-25
CN101443016A (zh)	2009-05-27
EP1854465A1 (en)	2007-11-14
US20100061975A1 (en)	2010-03-11
WO2007131737A3 (en)	2008-05-02
CA2652057A1 (en)	2007-11-22
AU2007251823B2 (en)	2012-09-06
CA2651354A1 (en)	2007-11-22
CA2652057C (en)	2015-07-07
ATE487483T1 (de)	2010-11-15
KR101403895B1 (ko)	2014-06-20

Publication	Publication Date	Title
SI2018169T1 (sl)	2011-02-28	Uporaba 4,17 beta-dihidroksiandrost-4-en-3-ona za zdravljenje raka
TW200612892A (en)	2006-05-01	Novel compounds
UA96308C2 (ru)	2011-10-25	Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
MX2009005460A (es)	2009-08-28	(s)-n-estereoisomeros de analogos de 7,8-saturados-4,5-epoxi-morfi nano.
TW200745003A (en)	2007-12-16	Novel compounds
UA95644C2 (ru)	2011-08-25	Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
TW200732296A (en)	2007-09-01	Novel compounds
MXPA05010682A (es)	2005-12-12	Compuestos novedosos.
TW200519075A (en)	2005-06-16	Novel compounds
MXPA05013366A (es)	2006-04-05	Derivados de benzazepina utiles para el tratamiento de enfermedades asociadas con el receptor 5ht2c.
MX2012002366A (es)	2012-03-29	Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
MY147677A (en)	2012-12-31	Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
UA83659C2 (ru)	2008-08-11	Антагонисты рецепторов p2x7 и их применение, фармацевтическая композиция на их основе, способ их получения (варианты)
TW200738659A (en)	2007-10-16	Novel compounds
TNSN08370A1 (en)	2009-12-29	Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TW200801029A (en)	2008-01-01	Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
GEP20074197B (en)	2007-09-10	5ht2c receptor modulators
EP4335510A3 (en)	2024-06-26	Method for inhibiting bone resorption
TW200531689A (en)	2005-10-01	Therapeutic agents
GB0611907D0 (en)	2006-07-26	Compounds
TW200640863A (en)	2006-12-01	Compounds which potentiate glutamate receptor and uses thereof in medicine
MX2007011847A (es)	2008-03-11	Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
UA98804C2 (ru)	2012-06-25	Катехоламиновые производные и фармацевтическая композиция на их основе
TW200621690A (en)	2006-07-01	Novel compounds
TW200635903A (en)	2006-10-16	Therapeutic agents